Drug Type Small molecule drug |
Synonyms DYP 688, DYP-688, DYP688 |
Target |
Action inhibitors |
Mechanism GNA11 inhibitors(G protein subunit alpha 11 inhibitors), GNAQ inhibitors(G protein subunit alpha q inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uveal Melanoma | Phase 2 | United States | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | Australia | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | France | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | Germany | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | Netherlands | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | Spain | 04 Jul 2022 | |
Uveal Melanoma | Phase 2 | Switzerland | 04 Jul 2022 |
Phase 1 | 66 | DYP688 12 mg/kg | quxcforwks(uziaqclarx) = a nearly dose-proportional exposure of total monoclonal antibody and active conjugated payload usgzpeplfu (sjwoprkxwv ) | Positive | 30 May 2025 |